Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Royal London Asset Management Ltd.

Royal London Asset Management Ltd. lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 251,205 shares of the medical research company’s stock after purchasing an additional 5,027 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Edwards Lifesciences were worth $18,597,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. Abacus Planning Group Inc. lifted its position in shares of Edwards Lifesciences by 0.3% during the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock worth $2,977,000 after purchasing an additional 140 shares in the last quarter. Bowman & Co S.C. raised its holdings in Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after acquiring an additional 148 shares in the last quarter. Moors & Cabot Inc. raised its holdings in Edwards Lifesciences by 0.3% in the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company’s stock valued at $4,041,000 after acquiring an additional 152 shares in the last quarter. Pegasus Asset Management Inc. raised its holdings in Edwards Lifesciences by 0.4% in the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock valued at $3,156,000 after acquiring an additional 159 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC raised its holdings in Edwards Lifesciences by 1.9% in the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after acquiring an additional 162 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on EW shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Morgan Stanley raised their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Citigroup raised their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Barclays increased their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Finally, The Goldman Sachs Group increased their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $70.46 on Friday. The firm’s fifty day moving average price is $71.42 and its 200 day moving average price is $70.36. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market cap of $41.42 billion, a price-to-earnings ratio of 10.11, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,189,770.56. This trade represents a 16.83 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 51,303 shares of company stock valued at $3,715,776. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.